注释ID

1184174568

变量_单倍型

NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A, NAT2*12A, NAT2*13A, NAT2*14A

基因

NAT2

药物名称(英)

hydralazine

药物名称(中)

肼屈嗪

PMID

24444407

类型

Efficacy

含义

no

记事

Only slow acetylators showed a significant decreased in systolic blood pressure (clinic, ambulatory 24h, ambulatory daytime, ambulatory night-time) and diastolic blood pressure (clinic, ambulatory night-time). P-value applies to all blood pressure measurements. Excerpt from paper " In our study we found 15 SNPs within the NAT2 coding region: rs72466456 (29C>T, 30T>A and 33C>A); rs1801279 (191G>A); rs1041983 (282C>T); rs1801280 (341T>C and 403C>G); rs1799929 (481C>T); rs1799930 (590G>A, 609G>T and 766A>G); rs1208 (803A>G, 824T>C and 838G>A); rs1799931 (857G>A)"

专家论述

NAT2 *4/*14A + *4/*5D + *4/*6B + *4/*7A + *5D/*12A + *5D/*13A + *6B/*12A + *6B/*13A (assigned as intermediate acetylator phenotype) is not associated with response to hydralazine in people with resistant hypertension.

等位基因

*4/*14A + *4/*5D + *4/*6B + *4/*7A + *5D/*12A + *5D/*13A + *6B/*12A + *6B/*13A

专家评论

备注

变体注释摘要

id	研究类型	特征类型
17866	cohort	Study Cohort